Solventum Corp. 10-Q Summary: Q2 2026
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026, for Solventum Corporation (NYSE: SOLV), a global healthcare company spun off from 3M in April 2024. The company operates through three reportable segments: MedSurg, Dental Solutions, and Health Information Systems. On August 5, 2026, the company announced it is evaluating strategic alternatives for its Health Information Systems business.
Key Financial Metrics
| Metric (Millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Net Sales | $2,209 | $2,161 | $4,216 | $4,231 |
| Gross Profit | $1,286 | $1,175 | $2,382 | $2,289 |
| Operating Income | $181 | $214 | $262 | $367 |
| Net Income | $92 | $90 | $105 | $227 |
| Diluted EPS | $0.53 | $0.51 | $0.60 | $1.30 |
| Cash from Operations (YTD) | $38 | $198 | $38 | $198 |
| Total Debt (Carrying Value) | $5,079 | N/A | $5,079 | N/A |
| Cash & Equivalents | $403 | N/A | $403 | N/A |
Note: YTD figures represent the six months ended June 30.
Material Changes vs. Prior Period
- Revenue: Q2 2026 sales increased 2.2% year-over-year, driven by 9.5% organic growth. This growth was partially offset by the loss of sales from the Purification and Filtration business divested in September 2025. Q2 sales were boosted by approximately $125 million in advanced customer ordering ahead of a July 2026 ERP deployment.
- Profitability: Operating income decreased 15.8% in Q2 and 28.6% YTD compared to 2025. The decline is primarily due to increased Corporate and Unallocated expenses, including $204 million in legal charges recognized in Q2 2026 (vs. $0 in Q2 2025) and restructuring costs.
- Cost of Sales: Cost of product as a percentage of sales decreased (47.5% in Q2 2026 vs. 51.9% in Q2 2025), largely due to a $100 million pre-tax benefit from IEEPA tariff refunds recognized in June 2026.
- Interest Expense: Net interest expense decreased significantly (Q2: $64M vs. $103M; YTD: $125M vs. $207M) due to lower debt outstanding.
Guidance, Outlook, and Risks
- Strategic Review: The company is reviewing strategic alternatives for its Health Information Systems segment to maximize shareholder value. No specific transaction or timeline is guaranteed.
- ERP Impact: Management anticipates Q3 2026 sales will be negatively impacted as customers normalize inventory levels following the advanced ordering in Q2.
- Restructuring: The "Transform for the Future" initiative is expected to generate $500 million in annual cost savings once fully implemented, with cumulative pretax costs of approximately $500 million.
- Legal Contingencies: Significant litigation risks remain, particularly regarding the Bair Hugger patient warming system (indemnified from 3M). Accrued litigation costs rose to $235 million as of June 30, 2026.
- Tariffs: While the company recognized a $100 million benefit from IEEPA tariff refunds, it continues to monitor new tariffs imposed under different authorities (Sections 122, 301, 338, and 232).
Investor Verification Checklist
- Legal Accruals: Verify the sustainability of the $204 million legal charge in Q2 and the adequacy of the $235 million accrued litigation liability, specifically regarding the Bair Hugger MDL.
- Revenue Quality: Assess the extent to which Q2 organic growth (9.5%) was driven by the $125 million of advanced ERP-related orders versus underlying demand.
- Health Information Systems: Monitor the progress of the strategic review for this segment and potential impacts on future earnings or asset sales.
- Cash Flow: Review the significant decrease in operating cash flow ($38M YTD 2026 vs. $198M YTD 2025) driven by higher incentive compensation payments and transition agreement exits.
- Debt Structure: Confirm the impact of the $5.0 billion senior notes portfolio on future interest expense as rates fluctuate.